Germany Recordati Rare Diseases aims to be a trusted partner in helping patients with rare diseases reach diagnosis and appropriate care sooner Rapid access to innovation alone does not solve the rare disease challenge in Germany. Despite being one of Europe’s most advanced pharmaceutical markets, patients still face long diagnostic journeys…
Germany Germany’s future competitiveness begins with the policy decisions we make today Scientific breakthroughs alone are not enough to shape the future of healthcare. They must be matched by the right policy environment, sustained investment, and a shared commitment to innovation. Daniel Steiners discusses how Roche is strengthening its position across…
Europe The goal is not only to generate scientific breakthroughs, but to ensure that these breakthroughs reach patients faster and more reliably Professor Gerd Geisslinger serves as Chair of Clinical Pharmacology at Goethe University Hospital and as Executive Director of the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), which is…
Korea As the world around us changes, we need to change with it Marie Antonia von Schönburg has been President and Chief Executive of the Korean-German Chamber of Commerce and Industry in Seoul for 16 months. With 26 years of experience across the global network of German Chambers abroad,…
Germany Germany remains one of Europe’s most important pharmaceutical markets, combining scientific excellence, strong clinical research capabilities, and early access to innovation. Yet as breakthrough therapies become more sophisticated and global competition for investment intensifies, maintaining that position will require more than scientific strength alone. Urs Voegeli, Managing Director of Johnson…
Germany Scientific breakthroughs are redefining what is possible in cancer care, yet the true test lies in translating discovery into meaningful and lasting patient benefit. Michael Baumann reflects on how the DKFZ is helping shape Germany’s evolving oncology ecosystem through national research networks, precision medicine, clinical trial infrastructure, and a renewed…
Germany Transformation often reveals itself not through grand declarations, but through the decisions organisations make about where to invest, what capabilities to build, and how they choose to serve patients. At Angelini Pharma Germany, that evolution is taking shape through a growing commitment to Brain Health, a resilient Consumer Health business,…
Germany Innovation, supply security, and sustainability are intertwined challenges for healthcare systems across Europe. For CSL, these conversations are part of everyday reality, from ensuring access to plasma-derived therapies and advancing treatments for rare diseases to navigating an evolving policy landscape in one of its most important markets. Annegret Wittich-Hoeffer, Cluster…
Germany Germany’s Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute for Drugs and Medical Devices (BfArM) outline how the Act attempts to revitalise clinical research in Germany, balancing faster procedures…
Germany Professor Stefan Vieths, president of Germany’s Paul-Ehrlich-Institut (PEI), explains how Europe’s most specialised biomedicines regulator is navigating a period of rapid transformation. Vieths traces the PEI’s 130-year evolution from a serum-testing institute into the federal authority overseeing vaccines, blood products, and advanced therapies; examines how Germany’s Medical Research Act is…
Germany Germany’s biotechnology sector finds itself at a critical inflection point as political ambition, scientific strength, and industrial policy begin to converge around a shared objective: positioning the country as a leading global biotechnology hub. Yet behind the momentum lies a more complex reality, shaped by financing constraints, regulatory fragmentation, scale-up…
Germany Germany’s research-based pharmaceutical industry is approaching a defining period as mounting pressure to curb healthcare expenditure clashes with the country’s long-established ambition to remain a leading hub for innovation, scientific research, and advanced manufacturing. Han Steutel, President of the vfa, cautions that although Germany continues to benefit from world-class scientific…
See our Cookie Privacy Policy Here
